Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees

Abstract

This is a commissioned report by a writing committee formed by the Society for Clinical Trials. The committee was formed with the objectives of 1) reviewing data monitoring guidelines for confirmatory (phase III) trials published by the National Institutes of Health, US Food and Drug Administration, Veterans Administration, and the International Conference on Harmonisation and 2) proposing corresponding guidelines for exploratory clinical trials (ie, most phase I and phase II trials and others not requiring a fully independent data monitoring committee). These trials typically involve fewer subjects and are of shorter duration than phase III trials. Nevertheless there are safety concerns, especially because these are often the first human trials for a new intervention. Recommendations are given for appropriate elements of a data monitoring plan, decision criteria for institution of a data monitoring committee (DMC), and critical elements for a DMC to consider in exploratory trials. Review and approval of data monitoring plans are suggested to fall under Institutional Review Board purview. Forming a committee with all the characteristics of a traditional phase III trial monitoring committee may be warranted for a small fraction of exploratory trials. Such a panel could consist of both trial investigators and outside members. The paper concludes with examples of data and safety monitoring practice from the University of Wisconsin Comprehensive Cancer Center and the AIDS Clinical Trials Groups.

Get full access to this article

View all access options for this article.

References

1. Ellenberg SS , Fleming TR , DeMets DL . Data monitoring committees in clinical trials: a practical perspective. John Wiley & Sons, 2002.

2. US National Institutes of Health . NIH policy for data and safety monitoring, 10 June, 1998, http://grants1.nih.gov/grants/guide/notice-files/not98-084.html, accessed 15 May 2006.

3. US National Institutes of Health . Guidance on reporting adverse events to Institutional Review Boards for NIH multicenter trials, 11 June, 1999, http://grants1.nih.gov/grants/guide/notice-files/not99-107.html, accessed 15 May 2006.

4. US National Institutes of Health . Further guidance on data and safety monitoring for phase I and II trials, OD-00-038, 5 June, 2000, http://grants1.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html, accessed 15 May 2006.

5. US Food and Drug Administration . Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees, 2006, http://www.fda.gov/cber/gdlns/clintrialdmc.htm, accessed 15 May 2006.

6. US Department of Veterans Affairs . Cooperative studies program: guidelines for the planning and conduct of cooperative studies. Office of Research and Development, January 2001.

7. International Conference on Harmonisation . E3-structure of clinical study reports, November 1995. www.ich.org, accessed 15 May 2006.

8. International Conference on Harmonisation . E6-good clinical practice: consolidated guidelines, May 1996, www.ich.org, accessed 15 May 2006.

9. International Conference on Harmonisation . E9-statistical principles for clinical trials, February 1998, www.ich.org, accessed 15 May 2006.

10.

10. University of Minnesota . IRB home page. Data safety monitoring. www.irb.umn.edu/guidance/dsm/index.cfm, accessed 15 May 2006.

11.

11. University of Wisconsin Comprehensive Cancer Center . Policy and procedures for data and safety monitoring. 30 May, 2002, www.uwccc.wisc.edu/ctro/SOPs/DSM_Plan_May30_2002.pdf, accessed 15 May 2006.

12.

12. National Cancer Institute Data and Safety Monitoring Guidelines . http://www.cancer.gov/clinicaltrials/conducting/dsm-guidelines, accessed 15 May 2006.

13.

13. Hibberd PL , Weiner DL . Monitoring participant safety in phase I and II interventional trials: Options and controversies. Journal of Investigative Medicine 2004; 52: 446–452.

14.

14. Sydes MR , Spiegelhalter DJ , Altman DG , Babiker AB , Parmar MKB and the DAMOCLES Group .Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials 2004; 1: 60–79.